Kamali Mahdieh, Hamadani Sedigheh, Neamatzadeh Hossein, Mazaheri Mahta, Zare Shehneh Masoud, Modaress Gilani Mitra, Haghighi Fatemeh
Department of Perinatology, School of Medicine, Tehran University Medical of Sciences, Tehran, Iran.
Maternal-Fetal and Neonatal Research Center, Tehran University Medical of Sciences, Tehran, Iran. Email:
Asian Pac J Cancer Prev. 2017 Jul 27;18(7):1743-1749. doi: 10.22034/APJCP.2017.18.7.1743.
Background: Previous studies have investigated the association of X-Ray Repair Cross-Complementing Group 2 (XRCC2) rs3218536 polymorphism with breast and ovarian cancer. However, this association remains conflicting. Therefore, we have performed the current systematic review and meta-analysis to clarify the association between XRCC2 rs3218536 polymorphism with risk of breast and ovarian cancer. Methods: We conducted a search in PubMed, Google Scholar and ISI Web of Science to select relevant studies on the association of XRCC2 rs3218536 polymorphism with breast and ovarian cancer susceptibility. We calculated the odds ratios (OR) and 95% confidence intervals (CI) for five genetic contrasts. In addition, a stratified analysis was conducted cancer type, ethnicity and HWE status. Results: A total of 17 studies with 5694 cases and 6450 controls for breast cancer and nine case-control studies with 4464 cases and 6353 controls for ovarian cancer were identified for the analysis of the association with XRCC2 rs3218536 polymorphism. The pooled ORs revealed that XRCC2 rs3218536 polymorphism was associated with breast cancer under the heterozygote contrast (AG vs. GG: OR = 0.929, 95% CI = 0.873-0.987, p=0.018) and ovarian cancer under dominant contrast (AA+AG vs. GG: OR = 0.725, 95% CI = 0.537-0.979, p=0.036) in the overall population. The stratified analysis indicated a significant association of XRCC2 rs3218536 polymorphism with breast and ovarian cancer risk among Caucasians. Conclusion: Inconsistent with previous meta-analysis, this meta-analysis shows that the XRCC2 rs3218536 polymorphism was associated with breast and ovarian cancer risk in overall population, especially among Caucasians.
既往研究探讨了X射线修复交叉互补基因2（XRCC2）rs3218536多态性与乳腺癌和卵巢癌的关联。然而，这种关联仍存在争议。因此，我们进行了当前的系统评价和荟萃分析，以阐明XRCC2 rs3218536多态性与乳腺癌和卵巢癌风险之间的关联。方法：我们在PubMed、谷歌学术和科学网（ISI Web of Science）中进行检索，以选择关于XRCC2 rs3218536多态性与乳腺癌和卵巢癌易感性关联的相关研究。我们计算了五种基因对比的比值比（OR）和95%置信区间（CI）。此外，还按癌症类型、种族和哈迪-温伯格平衡（HWE）状态进行了分层分析。结果：共纳入17项研究，其中乳腺癌病例5694例、对照6450例，以及9项病例对照研究，其中卵巢癌病例4464例、对照6353例，用于分析与XRCC2 rs3218536多态性的关联。汇总的OR值显示，在总体人群中，XRCC2 rs3218536多态性在杂合子对比（AG vs. GG：OR = 0.929，95%CI = 0.873 - 0.987，p = 0.018）下与乳腺癌相关，在显性对比（AA + AG vs. GG：OR = 0.725，95%CI = 0.537 - 0.979，p = 0.036）下与卵巢癌相关。分层分析表明，在白种人中，XRCC2 rs3218536多态性与乳腺癌和卵巢癌风险存在显著关联。结论：与既往荟萃分析不同，本荟萃分析表明，XRCC2 rs3218536多态性与总体人群尤其是白种人的乳腺癌和卵巢癌风险相关。
